About this trial

Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.

Eligibility criteria

Qualifiers

Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention

Disqualifiers

Non-symptomatic BPH

No treatment prescribed for BPH

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

7,500 Participants
are grouped into 1 trial group

Locations

26
Canada
Toronto Western Hospital, University Health Network TorontoOntario, Canada
McGill University Health Centre MontrealQuebec, Canada
University of Montreal Hospital Center Montreal Canada
Chile
Hospital Dr. Juan Morey La Unión La Unión Chile

Sponsors and collaborators

Société Internationale d'Urologie

Lead sponsor